【推荐】MorningBulletin金英证券公司

理财经验 阅读 36 2025-03-03 10:34:28

类别:投资策略 机构:金英证券(香港)有限公司研究员:金英证券(香港)研究所日期:2014-10-08

Sep 14 Macau GGR fell 12% YoY. Oct 14 likely to be still challenging.

That said, anti-graft drive may be winding down and mortgage ruleshave been substantially relaxed.

Stay OVERWEIGHT. Sector trading at below five-year mean. Top Picksare Galaxy Entertainment Group and Sands China.

What’s New

Sep 14 Macau GGR fell 12% YoY to MOP25.6b, bringing 9M14 GGR toMOP275.9b (+6% YoY). We believe VIP GGR was hurt by falling propertyprices and the anti-graft drive. Meanwhile, we believe mass market GGRgrowth continued to slow due to transit visa curbs (effective 1 Jul 2014)and anti-graft drive hurting the premium mass segment.

What’s Our View

While Oct 14 Macau GGR is most likely to be higher MoM due to the GoldenWeek holidays, we are unsure how it will fare YoY. The third CommunistParty Plenum (20-23 Oct 2014) may defer gambling plans by VIPs.

Furthermore, mass-gaming floors went smoke free yesterday. We estimatethe smoking ban will negatively impact mass market GGR growth by~13ppts at most.

That said, the Communist Party seemed to suggest the anti-graft drive maybe wound down in the near future. In addition, the PBOC has relaxedmortgage rules. These two key factors have the ability to arrest the wealthdestruction that has been negatively impacting VIP and premium massgamblers. We continue to believe Macau GGR growth will re-accelerategoing forward due to: (i) improving Chinese liquidity; (ii) stabilisingproperty prices; and (iii) new casino builds.

The average 12-month forward EV/EBITDA for Macau concessionaires isalready below its five-year mean at 11.3x and approaching -1SD to its fiveyearmean of 10.3x, suggesting downside risk is narrowing. StayOVERWEIGHT. Top Picks remain Galaxy Entertainment Group and SandsChina.

高端光学测量仪器

光学影像测量机

高精度光学测量仪

相关内容

版权声明:本文内容由互联网用户自发贡献,该文观点仅代表作者本人。 本站仅提供信息存储空间服务,不拥有所有权,不承担相关法律责任。如发现本站有涉嫌抄袭侵权/违法违规的内容, 请发送邮件至举报,一经查实,本站将立刻删除。
上一篇: 【推荐】MOM基金这么火到底有什么优势mom基金是什么意思 下一篇: 【推荐】MotleyFool美国大药厂新基制药面临的三大挑战美国爱力根公司官网

相关资讯